Treatment of recurrent pterygium with hyper dry human amniotic membrane(HD-AM)
- Conditions
- recurrence pterygium
- Registration Number
- JPRN-jRCTs042180103
- Lead Sponsor
- Hayashi Atsushi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
1) age: The patients who relatively have good Patient
2) overall status of (at the agreement acquisition) 20 years old or older
3) The patients whom pathologic proliferative tissue invaded in recurrent pterygium across limbus.
4) The patients whom it is judged to be available for observation, the testing that conformed to a study enforcement plan and a survey
1) Onset pterygium patient or pseudopterygium patients.
2)The patients whom a doctor judged safely for study period if it was difficult hospital visiting and to come home.
3)The patients who complicate eye infection with activity.
4)The patients who plan the enforcement of eye operations for evaluation eyes effective during study period in (we assume the agreement acquisition study initiation).
5)one eyes are the patients of enucleation eyes or evisceration eyes.
6)For the group medicine of the planned drug (dropping lotion in the eyes anesthetic agent, fluorescein) to use during study period, it is the patients with a history of the drug allergy.
7)The patients (saying that, however, the subjects who do not receive the study drug are possible) who participated in other studies or clinical studies within six months.
8) Pregnancy or the childbearing patients who may be pregnant or hope for pregnancy during study period or do not use appropriate contraception.
9) The patients who were judged to be inadequate as an object of this study in testing at agreement acquisition by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method